Drugs / GRF312
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07264517 | Nov 2025 → May 2026 | dry eye syndrome | Grifols, S.A. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-05-21 | Grifols Therapeutics LLC | Regulatory Grifols receives FDA clearance of IND application for Phase 2 trial of immunoglobulin drops for dry eye disease grifols.com ↗
Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced that the United States Food and Drug Administration (FDA) cleared the company’s Investigational New Drug (IND) application to initiate a Phase 2 trial evaluating its immunoglobulin (IG) drops – GRF312 Ophthalmic Solution – for what could become the first-ever ocular surface indication for an IG and a potential new treatment for dry eye disease (DED). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-05-21 | Grifols Therapeutics LLC | Grifols receives FDA clearance of IND application for Phase 2 trial of immunoglobulin drops for dry eye disease grifols.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRF312 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07264517 ↗ |
| Route | Other | “GRF312 5% Ophthalmic Solution” NCT07264517 ↗ |